Načítá se...
Practical management of patients with myelofibrosis receiving ruxolitinib
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, IN...
Uloženo v:
| Vydáno v: | Expert Rev Hematol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201600/ https://ncbi.nlm.nih.gov/pubmed/24083419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2013.827413 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|